Sue Friedman Provides an Overview of the ABOUT Network

Article

Sue Friedman, discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers.

Sue Friedman, Executive Director, FORCE (Facing Our Risk of Cancer Empowered), discusses the ABOUT Network, which is the first-ever patient-powered research registry created and governed by and for people affected by hereditary breast and ovarian cancers.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
TIL Presence in TNBC May Indicate Improved Survival

TIL Presence in TNBC May Indicate Improved Survival

May 13th 2024
Article

Patients with triple-negative breast cancer with an increased TIL count in breast tissue were more likely to have an improved distant recurrence-free survival.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Trastuzumab Deruxtecan Enhances PFS in Metastatic HR+/HER2-Low Breast Cancer

Trastuzumab Deruxtecan Enhances PFS in Metastatic HR+/HER2-Low Breast Cancer

April 30th 2024
Article

Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

ADCs Associated With Fatigue Among Patients With Breast Cancer

ADCs Associated With Fatigue Among Patients With Breast Cancer

April 29th 2024
Article

From journaling to delegating everyday tasks, nurses can teach patients how to cope with treatment-related fatigue.

Trastuzumab Biosimilar Receives FDA Approval for HER2-Overexpressing Breast and Gastric/GEJ Cancers

Trastuzumab Biosimilar Receives FDA Approval for HER2-Overexpressing Breast and Gastric/GEJ Cancers

April 29th 2024
Article

Trastuzumab-strf was approved for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

© 2024 MJH Life Sciences

All rights reserved.